Study type: In vitro · Status: Verified against declared source

Production of N-acetyl Tα1-HSA throughacetylation by RimJ.

Oncotarget · 2017

Study scale: Results are expressed as mean±SD (n=5), *indicate statistically significant difference (P 0.05) as compared with activity of Tα1(ZADAXIN®) at the same concentration.

Abstract only: Open source record

Product or molecular entity relationships

Thymosin Alpha 1: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

One of the biggest challenges for biotechnical production of Tα1 by genetic engineering is degradation of the small peptide by proteases in the host cell, leading to decreased production and interference in isolation from degraded fragments [4].

Methods

In contrast, fusion of Tα1 with a partner that doesn't require subsequent cleavage is a more promising strategy.

Scale or participants

Results are expressed as mean±SD (n=5), *indicate statistically significant difference (P 0.05) as compared with activity of Tα1(ZADAXIN®) at the same concentration.

Key findings

Thymosin alpha 1 (Tα1) is an important immunomodulating agent with various clinical applications.

Limitations and uncertainty

Nα-Acetylation is one of the most common protein modifications in eukaryotes, but rarely in prokaryotes [18].

Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.